LV12291B - Novel compounds and compositions for treating diseases associated with tryptase activity - Google Patents
Novel compounds and compositions for treating diseases associated with tryptase activity Download PDFInfo
- Publication number
- LV12291B LV12291B LVP-99-27A LV990027A LV12291B LV 12291 B LV12291 B LV 12291B LV 990027 A LV990027 A LV 990027A LV 12291 B LV12291 B LV 12291B
- Authority
- LV
- Latvia
- Prior art keywords
- compound
- alkylene
- hetero
- formula
- independently
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LVP-00-31A LV12459B (en) | 1996-07-30 | 2000-02-25 | Novel compounds and compositions for treating diseases associated with tryptase activity |
| LVP-00-30A LV12458B (en) | 1996-07-30 | 2000-02-25 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2313996P | 1996-07-30 | 1996-07-30 | |
| US89577297A | 1997-07-17 | 1997-07-17 | |
| PCT/US1997/013422 WO1998004537A1 (en) | 1996-07-30 | 1997-07-30 | Novel compounds and compositions for treating diseases associated with tryptase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV12291A LV12291A (lv) | 1999-06-20 |
| LV12291B true LV12291B (en) | 2000-04-20 |
Family
ID=26696778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-99-27A LV12291B (en) | 1996-07-30 | 1999-02-18 | Novel compounds and compositions for treating diseases associated with tryptase activity |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934293A1 (cs) |
| JP (1) | JP2001509787A (cs) |
| KR (1) | KR20000029679A (cs) |
| CN (1) | CN1073103C (cs) |
| AU (1) | AU733621B2 (cs) |
| CA (1) | CA2262542A1 (cs) |
| CZ (1) | CZ29799A3 (cs) |
| EE (1) | EE9900036A (cs) |
| FI (1) | FI990171L (cs) |
| HU (1) | HUP0003267A3 (cs) |
| LV (1) | LV12291B (cs) |
| NO (1) | NO990433L (cs) |
| NZ (1) | NZ333713A (cs) |
| PL (1) | PL331465A1 (cs) |
| SI (1) | SI9720047A (cs) |
| SK (1) | SK8599A3 (cs) |
| WO (1) | WO1998004537A1 (cs) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| EP1060171A2 (de) * | 1998-02-06 | 2000-12-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tryptase-inhibitoren |
| US6489327B1 (en) * | 1998-02-06 | 2002-12-03 | Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V. | Tryptase inhibitors |
| JP2003524598A (ja) * | 1998-09-04 | 2003-08-19 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規ピラノセン |
| CN1378538A (zh) * | 1999-08-10 | 2002-11-06 | 比克·古尔顿·劳姆贝尔格化学公司 | 二氮芳辛－二酮衍生物及其作为类胰蛋白酶抑制剂的应用 |
| CA2384763A1 (en) * | 1999-09-14 | 2001-03-22 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| AU1413301A (en) * | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
| DE19955476A1 (de) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| US7015325B2 (en) * | 1999-12-20 | 2006-03-21 | Altana Pharma Ag | Tryptase inhibitors |
| TR200402164T4 (tr) | 1999-12-20 | 2004-10-21 | Altana Pharma Ag | Triptaz inhibitörler |
| ES2225758T3 (es) | 2001-01-31 | 2005-03-16 | Altana Pharma Ag | Derivdos de diazocina y su uso como agentes inhibidores de la triptasa. |
| WO2002066420A2 (en) * | 2001-02-21 | 2002-08-29 | Altana Pharma Ag | Tryptase inhibitors |
| WO2002066430A1 (en) | 2001-02-21 | 2002-08-29 | Altana Pharma Ag | Tryptase inhibitors |
| US20040087792A1 (en) * | 2001-03-15 | 2004-05-06 | Thomas Martin | Tryptase-inhibitors |
| WO2002074732A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ATE540678T1 (de) | 2001-06-11 | 2012-01-15 | Xenoport Inc | Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ES2278928T3 (es) | 2001-06-19 | 2007-08-16 | Altana Pharma Ag | Inhibidores de triptasa. |
| CA2584338C (en) | 2004-11-04 | 2013-08-06 | Xenoport, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| MX2011006353A (es) * | 2008-12-19 | 2011-07-13 | Merz Pharma Gmbh & Co Kgaa | Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos. |
| TWI432188B (zh) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類 |
| FR3038605B1 (fr) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation |
| US12275687B2 (en) | 2017-05-12 | 2025-04-15 | Riken | Class A GPCR-binding compound modifier |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
| PL176941B1 (pl) * | 1993-03-12 | 1999-08-31 | Axys Pharmaceuticals | Nowe peptydy i środek farmaceutyczny do leczenia immunologicznych stanów zapalnych |
| US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
| AU2764495A (en) * | 1994-06-01 | 1995-12-21 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell mediated conditions |
| MX9702125A (es) * | 1994-09-23 | 1998-04-30 | Arris Pharm Corp | Composiciones y metodos para tratar condiciones inflamatorias mediadas por mastocitos. |
| AU713492B2 (en) * | 1995-03-24 | 1999-12-02 | Axys Pharmaceuticals, Inc. | Reversible protease inhibitors |
| TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 SK SK85-99A patent/SK8599A3/sk unknown
- 1997-07-30 CN CN97196877A patent/CN1073103C/zh not_active Expired - Fee Related
- 1997-07-30 EP EP97937066A patent/EP0934293A1/en not_active Withdrawn
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 JP JP50913698A patent/JP2001509787A/ja active Pending
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/en not_active Ceased
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/ko not_active Withdrawn
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/hu unknown
- 1997-07-30 FI FI990171A patent/FI990171L/fi unknown
- 1997-07-30 SI SI9720047A patent/SI9720047A/sl unknown
- 1997-07-30 NZ NZ333713A patent/NZ333713A/xx unknown
- 1997-07-30 EE EEP199900036A patent/EE9900036A/xx unknown
- 1997-07-30 PL PL97331465A patent/PL331465A1/xx unknown
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/cs unknown
- 1997-07-30 CA CA002262542A patent/CA2262542A1/en not_active Abandoned
-
1999
- 1999-01-29 NO NO990433A patent/NO990433L/no not_active Application Discontinuation
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998004537A1 (en) | 1998-02-05 |
| EE9900036A (et) | 1999-08-16 |
| AU733621B2 (en) | 2001-05-17 |
| NZ333713A (en) | 2000-12-22 |
| NO990433D0 (no) | 1999-01-29 |
| AU3967097A (en) | 1998-02-20 |
| SK8599A3 (en) | 2000-03-13 |
| CA2262542A1 (en) | 1998-02-05 |
| EP0934293A1 (en) | 1999-08-11 |
| CZ29799A3 (cs) | 1999-06-16 |
| CN1073103C (zh) | 2001-10-17 |
| KR20000029679A (ko) | 2000-05-25 |
| FI990171A7 (fi) | 1999-03-23 |
| FI990171L (fi) | 1999-03-23 |
| NO990433L (no) | 1999-03-25 |
| JP2001509787A (ja) | 2001-07-24 |
| HUP0003267A2 (hu) | 2001-06-28 |
| FI990171A0 (fi) | 1999-01-29 |
| SI9720047A (sl) | 1999-08-31 |
| CN1226892A (zh) | 1999-08-25 |
| LV12291A (lv) | 1999-06-20 |
| HUP0003267A3 (en) | 2002-02-28 |
| PL331465A1 (en) | 1999-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV12291B (en) | Novel compounds and compositions for treating diseases associated with tryptase activity | |
| AU686115B2 (en) | Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation | |
| SU1581221A3 (ru) | Способ получени (4-пиперидинилметил- или гетеро)-пуринов или их фармацевтически приемлемых солей с кислотами, или стереоизомеров | |
| US5607936A (en) | Substituted aryl piperazines as neurokinin antagonists | |
| CZ87097A3 (en) | Preparation for therapy and therapeutical methods for treating inflammations mediated by mast cells | |
| JP2007516212A (ja) | 自己免疫疾患の処置における使用のための２−アミノピリミジンおよび２−アミノピリジン−４−カルバメート | |
| WO2000027826A1 (de) | Neue pyrimidine, deren herstellung und verwendung | |
| US5574042A (en) | Imidazo [1,2-a] pyridines and their pharmaceutical use | |
| CZ20012562A3 (cs) | Amidové sloučeniny | |
| EP0224919A2 (en) | New thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | |
| US6489327B1 (en) | Tryptase inhibitors | |
| US7932247B2 (en) | M3 muscarinic acetylcholine receptor antagonists | |
| DE4243858A1 (de) | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung | |
| EP1057815B1 (en) | Cyclic amide compounds | |
| US20090142279A1 (en) | Novel m3 muscarinic acetylcholine receptor antagonists | |
| AU5625499A (en) | Novel pyranoses | |
| CA1305482C (en) | Piperidine derivatives, their preparation and their application in therapy | |
| AU2166901A (en) | Tryptase inhibitors | |
| JPH07330777A (ja) | チエノ［３，２−ｄ］ピリミジン−４−オン誘導体 | |
| NZ506614A (en) | Compounds for treating diseases associated with tryptase activity | |
| MXPA99001105A (en) | Novel compounds and compositions for treating diseases associated with tryptase activity | |
| Kaur et al. | Synthesis and antispasmodic activity evaluation of bis-(papaverine) analogues | |
| EP1368317B1 (en) | Tryptase inhibitors | |
| LT4587B (lt) | Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu | |
| LV12459B (en) | Novel compounds and compositions for treating diseases associated with tryptase activity |